<DOC>
	<DOCNO>NCT02287558</DOCNO>
	<brief_summary>This study evaluate patient &gt; 18 year age transfusion-dependent gastrointestinal bleeding due document gastrointestinal vascular ectasia without concurrent hereditary hemorrhagic telangiectasia ( HHT ) . This study focus document bleed site small bowel , include duodenum , jejunum ileum . Eligible patient endoscopically-documented site vascular ectasia require least 4 unit blood transfusion episodes intravenous iron administration precede four month .</brief_summary>
	<brief_title>Pomalidomide Hereditary Hemorrhagic Telangiectasia Transfusion-Dependent Vascular Ectasia : Phase I Study</brief_title>
	<detailed_description>This single-arm , open-label study investigate efficacy safety profile pomalidomide patient genetically-documented Hereditary Hemorrhagic Telangiectasia ( define characteristic mutation Eng , Alk-1 Smad-4 ) idiopathic vascular ectasia document mutation , lead refractory bleed small bowel . This study limit patient document bleed small bowel , include duodenum , jejunum ileum . Eligible patient dependent transfusion intravenous iron therapy ( require least 4 unit blood transfusion 4 iron infusion precede 4 month ) endoscopically-confirmed area vascular ecstasia . Therapy eligible patient initiate 1 mg daily dose pomalidomide . The principal investigator determine whether intrapatient dose escalation indicate base response patient 's bleeding first 30 day therapy . If dose escalation indicate , pomalidomide increase investigator 's discretion maximal dose 5 mg/day . Cessation GI bleeding define maintenance stable hemoglobin without blood transfusion intravenous iron therapy 4 week period . Once GI bleeding cease , patient maintain stable pomalidomide dose additional 4 month , dose taper 1 mg per month , bleed recurs . Patients follow total six month post-therapy determine whether response maintain .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Transfusion least 4 unit blood and/or four dos intravenous iron precede four month . 3 . Recurrent bleed least one previous interventional endoscopic procedure 4 . Platelet count ≥ 125,000/µl 5 . WBC ≥ 4,000/µl 6 . Normal prothrombin ( PT ) activate partial thromboplastin time ( aPTT ) 7 . Endoscopicallydocumented angiodysplasia and/or arteriovenous malformation involve small bowel 8 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day prior within 24 hour prescribe pomalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take pomalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even vasectomy . 9 . Ability understand sign inform consent 10 . All study participant must register mandatory POMALYST REMS™ program , willing able comply requirement POMALYST REMS™ program 1 . Pregnancy ( must exclude two urine serum test βHCG woman childbearing potential ) . Pregnancy Testing Must follow pregnancy test requirement outline POMALYST REMS™ program . 2 . Breast feed 3 . Renal insufficiency , serum creatinine &gt; 2.0 mg/dl 4 . Hepatic insufficiency , bilirubin &gt; 2.0 transaminase &gt; 3.0 x normal 5 . Previous treatment Thalidomide imid drug within previous 12 month 6 . History prior thromboembolism know thrombophilia 7 . Peripheral neuropathy , determine neurologic consultation 8 . Underlying hypoproliferative anemia ( i.e . myelodysplasia ) 9 . Inherited significant acquire coagulopathy ( i.e . hemophilia , advance liver disease ) 10 . Chronic aspirin , NSAID therapy , anticoagulation therapy antiplatelet agent 11 . Currently enrol interventional trial 12 . Known hypersensitivity thalidomide lenalidomide . 13 . The development erythema nodosum characterize desquamate rash take thalidomide , similar drug . 14 . Anything investigator 's opinion likely interfere completion study † A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HHT</keyword>
	<keyword>CASE4Z14</keyword>
	<keyword>Pomalidomide</keyword>
</DOC>